Charité-ko ikertzaileekin lankidetzan egindako argitalpenak (53)

2024

  1. Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology

    PLoS Computational Biology, Vol. 20, Núm. 2

  2. Embolization of percutaneous left atrial appendage closure devices: timing, management and clinical outcomes

    Cardiovascular Revascularization Medicine

  3. Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: A prospective study

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 1

  4. Graft-versus-Host Disease Prophylaxis with Post- Transplantation Cyclophosphamide in Chronic Myeloid Leukemia Patients Undergoing Allogeneic Hematopoietic Cell Transplantation from an Unrelated or Mismatched Related Donor: A Comparative Study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT)

    Transplantation and Cellular Therapy, Vol. 30, Núm. 1, pp. 93.e1-93.e12

  5. Profiling the dysregulated immune response in sepsis: overcoming challenges to achieve the goal of precision medicine

    The Lancet Respiratory Medicine, Vol. 12, Núm. 4, pp. 305-322

  6. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

    American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  4. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

    Leukemia, Vol. 37, Núm. 7, pp. 1521-1529

  5. Severe cytopenia after CD19 CAR T-cell therapy: A retrospective study from the EBMT Transplant Complications Working Party

    Journal for ImmunoTherapy of Cancer, Vol. 11, Núm. 4

2022

  1. Building a Healthcare Alliance for Resourceful Medicine Offensive Against Neoplasms in Hematology Added Value Framework for Hematologic Malignancies: A Comparative Analysis of Existing Tools

    Value in Health, Vol. 25, Núm. 10, pp. 1760-1767

  2. Corrigendum to “OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT” [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4](S2152265021X00122)

    Clinical Lymphoma, Myeloma and Leukemia

  3. Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study

    Liver International, Vol. 42, Núm. 8, pp. 1891-1901

  4. Proposed European Competence Network on Mastocytosis—American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2025-2038.e1

  5. Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM Consortium

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 8, pp. 2015-2024

2021

  1. A generic emergency protocol for patients with inborn errors of metabolism causing fasting intolerance: A retrospective, single-center study and the generation of www.emergencyprotocol.net

    Journal of Inherited Metabolic Disease, Vol. 44, Núm. 5, pp. 1124-1135

  2. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 463-475

  3. NEMHESYS - European Perspective on the Implementation of Next-generation Sequencing Into Clinical Diagnostics

    HemaSphere, Vol. 5, Núm. 3, pp. E541

  4. The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

    The Lancet Respiratory Medicine, Vol. 9, Núm. 6, pp. 622-642